Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company’s web site at www.palatin.com.
- 17 years ago
QualityStocks
Palatin Technologies, Inc. (AMEX: PTN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…